Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial
- 1 July 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Allergy and Clinical Immunology
- Vol. 146 (1), 137-146.e3
- https://doi.org/10.1016/j.jaci.2020.05.019
Abstract
No abstract availableKeywords
Funding Information
- Emergency Research Project of Tongji Hospital
- Emergency Research Project of Tongji Hospital of Huazhong University of Science and Technology (2020kfyXGYJ045)
- Emergency Research Project of Hubei province (2020FCA006)
This publication has 35 references indexed in Scilit:
- Chemokines and Chemokine Receptors in Lymphoid Tissue DynamicsAnnual Review of Immunology, 2016
- IL-12p40: an inherently agonistic cytokineTrends in Immunology, 2007
- Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndromeRespirology, 2006
- VEGF receptor signalling ? in control of vascular functionNature Reviews Molecular Cell Biology, 2006
- Multiple organ infection and the pathogenesis of SARSThe Journal of Experimental Medicine, 2005
- Persistence of lung inflammation and lung cytokines with high-resolution CT abnormalities during recovery from SARSRespiratory Research, 2005
- Analysis of Serum Cytokines in Patients with Severe Acute Respiratory SyndromeInfection and Immunity, 2004
- Plasma inflammatory cytokines and chemokines in severe acute respiratory syndromeClinical and Experimental Immunology, 2004
- Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective studyThe Lancet, 2003
- Macrophage inflammatory protein-1Cytokine & Growth Factor Reviews, 2002